PROTEOMIC IDENTIFICATION AND CHARACTERIZATION OF HEPATIC GLYOXALASE 1 DYSREGULATION IN NON-ALCOHOLIC FATTY LIVER DISEASE
Main Article Content
Keywords
Non-alcoholic fatty liver disease, Glyoxalase 1, Proteomic analysis, Liver steatosis, Hepatic dysregulation, Methylglyoxal
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a prevalent liver condition characterized by excessive fat accumulation in the liver, which can lead to liver dysfunction and other metabolic disorders.
Objective: To identify and characterize the proteomic changes associated with the dysregulation of hepatic glyoxalase 1 in patients with non-alcoholic fatty liver disease.
Methods: The study included 55 patients diagnosed with NAFLD. Proteomic analysis was conducted on liver tissue samples to quantify GLO1 expression levels and assess its functional alterations. Techniques such as mass spectrometry and Western blotting were used to identify the proteomic profile and characterize the changes in GLO1.
Results: The proteomic analysis revealed that the expression of GLO1 was significantly reduced in the hepatic tissue of NAFLD patients compared to healthy controls. Specifically, the average GLO1 expression level in NAFLD patients was 35% ± 5% of the level observed in controls (p < 0.01). In severe cases of NAFLD, GLO1 expression was further reduced to 20% ± 3% of the control levels. A strong inverse correlation was observed between GLO1 expression and the degree of liver steatosis (r = -0.75, p < 0.001). Patients with advanced steatosis (grade 3) had the lowest GLO1 levels, averaging 18% ± 2% of control values, while those with mild steatosis (grade 1) had levels averaging 42% ± 4%.
Conclusion: Hepatic glyoxalase 1 is significantly dysregulated in non-alcoholic fatty liver disease, with reduced expression and altered activity contributing to the progression of the disease. These findings highlight the importance of GLO1 as a potential therapeutic target in the management of NAFLD.
References
2. Loomba, R. and Sanyal, A.J., 2013. The global NAFLD epidemic. Nature Reviews Gastroenterology & Hepatology, 10, pp.686–690. doi: 10.1038/nrgastro.2013.171.
3. Welsh, J.A., Karpen, S. and Vos, M.B., 2013. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. The Journal of Pediatrics, 162, pp.496–500. doi: 10.1016/j.jpeds.2012.08.043.
4. Anderson, E.L., Howe, L.D., Jones, H.E., Higgins, J.P., Lawlor, D.A. and Fraser, A., 2015. The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis. PLoS One, 10, p.e0140908. doi: 10.1371/journal.pone.0140908.
5. Musso, G., Gambino, R., Cassader, M. and Pagano, G., 2011. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine, 43, pp.617–649. doi: 10.3109/07853890.2010.518623.
6. Feldstein, A.E., Charatcharoenwitthaya, P., Treeprasertsuk, S., Benson, J.T., Enders, F.B. and Angulo, P., 2009. The natural history of non-alcoholic fatty liver disease in children: A follow-up study for up to 20 years. Gut, 58, pp.1538–1544. doi: 10.1136/gut.2008.171280.
7. Moore, J.B., 2010. Non-alcoholic fatty liver disease: The hepatic consequence of obesity and the metabolic syndrome. Proceedings of the Nutrition Society, 69, pp.211–220. doi: 10.1017/S0029665110000030.
8. Schwimmer, J.B., Celedon, M.A., Lavine, J.E., Salem, R., Campbell, N., Schork, N.J. et al., 2009. Heritability of nonalcoholic fatty liver disease. Gastroenterology, 136, pp.1585–1592. doi: 10.1053/j.gastro.2009.01.050.
9. Anstee, Q.M., Seth, D. and Day, C.P., 2016. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology, 150, pp.1728–1744.e7. doi: 10.1053/j.gastro.2016.01.037.
10. Kenneally, S., Sier, J.H. and Moore, J.B., 2017. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: A systematic review. BMJ Open Gastroenterology, 4(1), p.e000139. doi: 10.1136/bmjgast-2017-000139.
11. Gibson, P.S., Lang, S., Dhawan, A., Fitzpatrick, E., Blumfield, M.L., Truby, H. et al., 2017. Systematic review: Nutrition and physical activity in the management of paediatric non-alcoholic fatty liver disease. Journal of Pediatric Gastroenterology and Nutrition, 65(2), pp.141–149. doi: 10.1097/MPG.0000000000001624.
12. Machado, M.V. and Cortez-Pinto, H., 2013. Non-invasive diagnosis of non-alcoholic fatty liver disease: A critical appraisal. Journal of Hepatology, 58, pp.1007–1019. doi: 10.1016/j.jhep.2012.11.021.
13. Joo, I., Lee, J.M., Yoon, J.H., Jang, J.J., Han, J.K. and Choi, B.I., 2014. Nonalcoholic fatty liver disease: Intravoxel incoherent motion diffusion-weighted MR imaging-an experimental study in a rabbit model. Radiology, 270, pp.131–140. doi: 10.1148/radiol.13122506.
14. Loomba, R., Wolfson, T., Ang, B., Hooker, J., Behling, C., Peterson, M. et al., 2014. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. Hepatology, 60, pp.1920–1928. doi: 10.1002/hep.27362.
15. Moore, J.B. and Weeks, M.E., 2011. Proteomics and systems biology: Current and future applications in the nutritional sciences. Advances in Nutrition, 2, pp.355–364. doi: 10.3945/an.111.000554.
16. Su, W., Wang, Y., Jia, X., Wu, W., Li, L., Tian, X. et al., 2014. Comparative proteomic study reveals 17beta-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. Proceedings of the National Academy of Sciences of the United States of America, 111, pp.11437–11442. doi: 10.1073/pnas.1410741111.
17. Fitzpatrick, E. and Dhawan, A., 2014. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World Journal of Gastroenterology, 20, pp.10851–10863. doi: 10.3748/wjg.v20.i31.10851.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Imran Joher
Assistant Professor of Medicine, Sharif Medical and Dental College, Lahore - Pakistan
Dr Abdul Sadiq
Acting Professor, Department of Biochemistry, Jhalawan Medical College Khuzdar, Balochistan - Pakistan
Dr Muhammad Saeed
Associate Professor, Department of Biochemistry, Bolan Medical College, Quetta - Pakistan
Dr Shoaib Ahmed
Associate Professor of Biochemistry, Rai Medical College, Sargodha - Pakistan
Dr Muhammad Imran Ashraf
Associate Professor, Pharmacology Department, Allama Iqbal Medical College, Lahore - Pakistan
Dr Rao Salman Aziz
Associate Professor, Pharmacology Department, Rashid Latif Medical & Dental College, Lahore - Pakistan